Section 4 of 6
Clinical evidence
214 evidence topics · 51 sources
Study summaries
ARCHER II
Objective
Primary purpose: reduction of vision loss with monthly injections
Main and secondary objectives in the EU trial record
Confirmation of the phase 2 ARCHER findings
Vision protection at Months 15 and 24
Location and study date
Completion of enrollment in July 2025
Regions of the study sites and of enrolled participants
Expected timing of the Month 15 assessment and of study completion
Study design
Phase 3, randomized, double-masked, sham-controlled design
Randomization ratio and masking through Month 24
Masked and unmasked study roles
Study periods: screening, 24-month treatment, and Month 24 visit
Single protocol analyzed as two sub-studies for the United States filing
Original design announced in 2023: approximately 400 participants randomized 1:1 for 12 months
Second head-to-head phase 3 trial against pegcetacoplan no longer planned
Design informed by the phase 2 ARCHER trial
Open-label extension offered after Month 24
Eligibility criteria
Age, diagnosis, and study duration
Lesion size, multifocality, and junctional hyperautofluorescence on fundus autofluorescence
Best-corrected visual acuity of 45 to 83 letters
Reason for excluding eyes with baseline acuity below 45 letters
Fellow-eye choroidal neovascularization and fellow-eye GA treatment
Exclusion of study-eye choroidal neovascularization, prior intravitreal or AMD treatment, and uveitis
Exclusion for myopia, uncontrolled glaucoma, and prior ocular surgery in the study eye
Treatment
Vonaprument 5 mg monthly or sham monthly for 24 months
Study outcomes
Rationale for using confirmed best-corrected visual acuity loss of 15 or more ETDRS letters as the primary endpoint
Primary endpoints: confirmed loss of 15 or more letters through Month 15 and through Month 24
Month 24 dual primary endpoint added in August 2026
Landmark analysis and alpha split between Month 15 and Month 24
Timing of the primary analysis in earlier disclosures
Secondary endpoints: time to confirmed loss, low-luminance acuity, ellipsoid zone, and safety
FDA alignment on the endpoint without a lesion-growth requirement
Prior use of the endpoint in ophthalmology approvals
Functional primary endpoints of approved retinal products
| Indication and product | Functional primary endpoint |
|---|---|
| Wet AMD, Lucentis | “Trial 1 and 2: BCVA ≥15-letter change” |
| Wet AMD, Eylea and Eylea HD | “BCVA ≥15-letter change/Mean BCVA change” |
| Wet AMD, Vabysmo | “Mean BCVA change” |
| DME, Lucentis | “BCVA ≥15-letter change” |
| DME, Iluvien | “BCVA ≥15-letter change” |
| DME, Ozurdex | “BCVA ≥15-letter change” |
| GA | “No Approved Vision-Preserving Treatments” |
Clinical meaning of a loss of 15 or more letters
Frequency of loss of 15 or more letters in prior GA datasets
Approved GA therapies: anatomic endpoint without demonstrated visual benefit
“The approval of pegcetacoplan and avacincaptad was based on an anatomic endpoint of a reduction in the rate of GA expansion over time. However, functional data from two phase 3 clinical trials for each drug demonstrated no visual benefit to patients in the treatment groups.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Although change in visual acuity is often the primary endpoint in clinical trials for new retinal drug applications, approval of a drug based solely on anatomic outcomes is not unprecedented.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Basis in a prespecified analysis of the phase 2 ARCHER trial, whose primary endpoint was lesion growth
Enrichment of the ARCHER II population and expected event rate
Statistical analysis description
Number of participants (Planned and analyzed)
Enrollment of 659 participants
Statistical power and sub-study size
Number analyzed
No evidence found.
Description of analysis sets
Single study for the EU filing and two sub-studies of about 330 participants each for the United States filing
Sequence of the single-study and sub-study analyses
Definitions of efficacy and safety analysis populations
No evidence found.
Results
Participant disposition
Discontinuation below 10% and compliance above 95% as of August 2026
Disposition by treatment arm
No evidence found.
Baseline characteristics
Demographic and structural characteristics compared with ARCHER
| Characteristic | ARCHER (N = 270) | ARCHER II (N = 659) |
|---|---|---|
| Age, mean (SD) | “80.0 (8.2)” | “78.4 (8.0)” |
| Female | “61.5%” | “63.0%” |
| GA lesion size (mm2), mean (SD) | “7.36 (4.01)” | “7.23 (3.49)” |
| GA lesion location, subfoveal | “51.9%” | “54.8%” |
| Total EZ loss, mm2 (% of total area lost) | “12.7 (35.3%)” | “12.3 (34.3%)” |
Visual acuity characteristics compared with ARCHER
| Characteristic | ARCHER (N = 270) | ARCHER II (N = 659) |
|---|---|---|
| Mean BCVA (SD), letters | “58.4 (16.2)” | “65.8 (10.5)” |
| Baseline BCVA below 45 letters | “23.3%” | “0.0%” |
| Mean LLVA (SD), letters | “33.0 (16.9)” | “38.3 (17.2)” |
| Mean LLVD (SD), letters | “25.7 (16.9)” | “27.6 (15.6)” |
| LLVD below 30 letters | “62.4%” | “60.7%” |
Proportions with foveal lesions and with low-luminance deficit below 30 letters
Baseline characteristics by treatment arm
No evidence found.
Efficacy results
No evidence found.
Health-related quality of life and patient-reported outcomes
No evidence found.
Safety results
No evidence found.
Study limitations
Summary: design features and absence of results
As of November 15, 2026, no efficacy or safety result of ARCHER II has been released; the sponsor expects the independent Data Monitoring Committee assessment of the Month 15 primary endpoint in the fourth quarter of 2026, sub-study results in the first quarter of 2027 if the endpoint is met, and study completion with the Month 24 analyses in the third quarter of 2027. The only disclosed trial-level data are pooled, masked baseline characteristics of 659 participants and sponsor statements on retention (90%), discontinuation (below 10%), and compliance (above 95%); baseline data by arm and the numbers analyzed have not been published.
The design has changed since it was first announced. In December 2023 the trial was planned with approximately 400 participants randomized 1:1 and a primary endpoint assessed through 12 months; the enrolled trial randomized 659 participants 2:1 to monthly vonaprument 5 mg or sham. The timing of the primary analysis was described as 12 to 18 months from dosing initiation in 2024, at least 12 months in July 2025, 12 to 15 months in December 2025, and Month 15 in 2026. A Month 24 dual primary endpoint was added in August 2026 while masked follow-up was ongoing, with alpha allocated between the two timepoints (the majority to Month 15); the sponsor's Form 10-Q states that there is no assurance regulators will accept the amended dual primary endpoint design.
For the U.S. filing, the single protocol is divided into two pre-defined sub-studies of about 330 participants each to address the FDA two-trial recommendation, so the replication rests on two subsets of one trial with a shared protocol and conduct. The sham comparator is an injection-free procedure, and the planned injection-controlled trial against pegcetacoplan (ARROW) was dropped in March 2025, so ARCHER II will provide no comparison with an approved GA therapy. The endpoint rationale rests on the phase 2 ARCHER trial, in which the 15-letter loss analysis was prespecified while the primary lesion-growth endpoint “did not reach statistical significance”. Eligibility excludes eyes with baseline BCVA below 45 letters, which the sponsor states was chosen because few such eyes had 15-letter loss events in ARCHER; results will therefore not describe eyes with lower baseline acuity. Patient-reported outcomes are listed as a secondary objective in the EU record, and no instrument has been named.
Regulatory acceptance of the amended dual primary endpoint design
Longer timeline from the added Month 24 endpoint and extension study
Data Monitoring Committee futility assessment
ARCHER
Objective
Registered objective: effect of intravitreal ANX007 on GA lesion growth rate
Location and study date
Registered study dates
| Milestone | Registry record |
|---|---|
| Study start (actual) | “2021-02-26” |
| Primary completion (actual) | “2023-03-28” |
| Study completion (actual) | “2023-09-13” |
Study site countries
| Country | Example site location in the registry record |
|---|---|
| United States | “Boston, Massachusetts, United States” |
| Australia | “Adelaide, South Australia, Australia” |
| New Zealand | “Wellington, New Zealand” |
Share of participants enrolled in the United States
Study design
Registered design elements
| Design element | Registry record |
|---|---|
| Phase | “Phase 2” |
| Allocation | “Randomized” |
| Intervention model | “Parallel Assignment” |
| Masking | “Quadruple” |
| Primary purpose | “Treatment” |
Randomized, double-masked, sham-controlled design with stratification
Twelve-month treatment period followed by six months off treatment
Eligibility criteria
Key inclusion criteria
Key exclusion criteria
Enrollment of participants at high risk of progression
Treatment
Registered arms and interventions
| Arm | Quoted registry description |
|---|---|
| ANX007 Group 1, experimental | “ANX007 administered every month” |
| ANX007 Group 2, experimental | “ANX007 administered every other month” |
| Sham Group 3, sham comparator | “Sham injection administered every month” |
| Sham Group 4, sham comparator | “Sham injection administered every other month” |
| ANX007 formulation and route | “Form: solution for injection; Route of Administration: IVT” |
| Sham procedure | “Form and Route of Administration: pressure to mimic IVT injection” |
Dose, schedule, and randomized arms
Injection volume in phase 2
Dosing schedules planned at trial initiation
Study outcomes
Rationale for using rate of change in geographic atrophy lesion area by fundus autofluorescence as the primary endpoint
Primary endpoint definition: GA lesion area slope by FAF through Month 12
Sponsor rationale at trial start: natural history data and enrichment for fast progressors
Non-foveal lesions as a risk factor for faster lesion growth
Regulatory acceptance of GA expansion measured by FAF
“After extensive discussions, the FDA agreed that an acceptable clinical endpoint for GA could be the rate or extent of anatomic progression of GA in treatment and placebo groups.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Fundus autofluorescence (FAF) imaging is the standard metric used by the FDA for assessing GA expansion.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“However, the relationship between function and altered autofluorescence at the GA border is still not clear.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Sponsor view after the readout: FAF measures the retinal pigment epithelium
Prespecified visual function endpoints
Best corrected visual acuity: ETDRS letter score
BCVA loss of 15 or more letters: definition and rationale
Low-luminance visual acuity and low-luminance deficit
Statistical analysis description
Number of participants (Planned and analyzed)
Participants enrolled
| Enrollment type | Participants |
|---|---|
| Actual | “270” |
Optical coherence tomography subpopulation
Description of analysis sets
Intent-to-treat and safety populations
Primary endpoint analysis population: non-subfoveal participants
Low-luminance event analyses: participants with a postbaseline measurement
Primary endpoint model: linear mixed effect model
Visual acuity analyses: chi-square test and MMRM in the ITT population
Optical coherence tomography analysis population
Results
Participant disposition
Registry participant flow through the overall study
| Milestone or reason | ANX007 EM | ANX007 EOM | Sham |
|---|---|---|---|
| Started | “89” | “92” | “89” |
| Received at least 1 dose of study drug | “89” | “92” | “89” |
| Completed | “73” | “77” | “76” |
| Not completed | “16” | “15” | “13” |
| Adverse event | “4” | “7” | “3” |
| Death | “0” | “0” | “1” |
| Lost to follow-up | “2” | “2” | “1” |
| Other than specified | “1” | “0” | “1” |
| Physician decision | “1” | “0” | “1” |
| Protocol violation | “1” | “1” | “0” |
| Withdrawal by subject | “7” | “5” | “6” |
Counts reported per participant
Treatment discontinuation by arm
| Measure | Sham pooled | ANX007 EM | ANX007 EOM |
|---|---|---|---|
| Discontinued treatment | “10 (11.2%)” | “13 (14.6%)” | “11 (12.0%)” |
Baseline characteristics
Registry baseline characteristics, ITT population
| Characteristic | ANX007 EM | ANX007 EOM | Sham | Total |
|---|---|---|---|---|
| Participants | “89” | “92” | “89” | “270” |
| Age, years, mean (SD) | “79.7(8.64)” | “80.5(8.53)” | “79.8(7.49)” | “80.0(8.22)” |
| Female, participants | “47” | “60” | “59” | “166” |
| Male, participants | “42” | “32” | “30” | “104” |
| Hispanic or Latino, participants | “1” | “2” | “3” | “6” |
| White, participants | “87” | “89” | “87” | “263” |
| Asian, participants | “1” | “2” | “2” | “5” |
| Study eye GA lesion size, mm², mean (SD) | “7.2789(3.96342)” | “7.5284(4.09946)” | “7.2802(3.98783)” | “7.3643(4.00505)” |
| BCVA, ETDRS letters, mean (SD) | “58.8(17.19)” | “57.9(15.30)” | “58.5(16.23)” | “58.4(16.19)” |
| LLVA, ETDRS letters, mean (SD) | “35.3(16.41)” | “29.6(15.72)” | “34.2(18.05)” | “33.0(16.86)” |
| LLVA and LLVD, participants analyzed | “87 participants” | “91 participants” | “85 participants” | “263 participants” |
| LLVD, ETDRS letters, mean (SD) | “23.5(16.08)” | “28.3(18.39)” | “25.0(15.70)” | “25.7(16.86)” |
Lesion location, lesion size category, fellow-eye CNV, and multifocality
| Characteristic | Sham pooled (N=89) | Vonaprument EM (N=89) | Vonaprument EOM (N=92) |
|---|---|---|---|
| Foveal lesion | “49.4%” | “57.3%” | “53.3%” |
| GA lesion < 7.5 mm² | “61.8%” | “58.4%” | “57.6%” |
| Fellow eye CNV | “22.5%” | “24.7%” | “17.4%” |
| Multifocality, n (%) | “65 (73.0%)” | “61 (68.5%)” | “67 (72.8%)” |
Company summary of baseline characteristics
Efficacy results
Primary endpoint: rate of change in geographic atrophy lesion area through month 12, registry results
| Measure | ANX007 EM | ANX007 EOM | ANX007 Pooled | Sham |
|---|---|---|---|---|
| Participants analyzed | “38” | “43” | “81” | “45” |
| Rate of change (slope), mean (SE), mm²/year | “1.9902(0.36343)” | “2.1575(0.34824)” | “2.0837(0.30177)” | “1.9019(0.34239)” |
| Change from baseline to month 12, least squares mean (SE), mm² | “2.3547(0.26452)” | “2.5782(0.24317)” | “2.4835(0.18003)” | “2.3170(0.23142)” |
Primary endpoint: company-reported reduction in lesion growth
Lesion growth by study period: additional analysis
Confirmed BCVA ≥15-letter loss: registry event counts, secondary outcome
Confirmed BCVA ≥15-letter loss: topline company counts and event definition
| Measure | Sham (n=89) | EM (n=89) | EOM (n=92) | ANX007 pooled (n=181) |
|---|---|---|---|---|
| Participants with ≥15-letter loss through month 12 | “21.3% (19/89)” | “5.6% (5/89)” | “10.9% (10/92)” | “8.3% (15/181)” |
| p-value vs sham | “--” | “0.0021” | “0.055” | “0.0024” |
Confirmed BCVA ≥15-letter loss: final data under two event definitions
| Event definition and measure | Sham | Vonaprument EM | Vonaprument EOM |
|---|---|---|---|
| Through month 12 or last visit: participants with loss | “19/89” | “5/89” | “9/92” |
| Through month 12 or last visit: percentage | “21.3%” | “5.6%” | “9.8%” |
| Through month 12 or last visit: nominal p-value vs pooled sham | “---” | “0.0021” | “0.032” |
| Month 12 event confirmed at month 15: participants with loss | “15/89” | “4/89” | “8/92” |
| Month 12 event confirmed at month 15: percentage | “16.9%” | “4.5%” | “8.7%” |
| Month 12 event confirmed at month 15: nominal p-value vs pooled sham | “---” | “0.0076” | “0.0994” |
Confirmed BCVA ≥15-letter loss: analysis type and nominal significance
Time to confirmed BCVA ≥15-letter loss: Kaplan-Meier hazard ratios
“73% Risk Reduction Vonaprument EM” (opens the source at this quote in a new tab)
“HR (CI) = 0.272 (0.090 to 0.819); Nominal p = 0.0119” (opens the source at this quote in a new tab)
“50% Risk Reduction Vonaprument EOM” (opens the source at this quote in a new tab)
“HR (CI) = 0.504 (0.214 to 1.189); Nominal p = 0.1098” (opens the source at this quote in a new tab)
Time to confirmed BCVA ≥15-letter loss: hazard ratios as presented in 2024
“53% Risk Reduction ANX007 EOM” (opens the source at this quote in a new tab)
“HR (CI) = 0.504 (0.214 to 1.190); p = 0.0788” (opens the source at this quote in a new tab)
“73% Risk Reduction ANX007 EM” (opens the source at this quote in a new tab)
“HR (CI) = 0.272 (0.090 to 0.819); p = 0.0098” (opens the source at this quote in a new tab)
Confirmed BCVA ≥10-letter and ≥20-letter loss: sensitivity analysis
| Threshold and measure | Sham | EM | EOM |
|---|---|---|---|
| ≥10-letter loss: participants with loss | “23/89” | “14/89” | “19/92” |
| ≥10-letter loss: percentage | “25.8%” | “15.7%” | “20.7%” |
| ≥10-letter loss: nominal p-value vs sham | “---” | “0.096” | “0.408” |
| ≥20-letter loss: participants with loss | “15/89” | “4/89” | “6/92” |
| ≥20-letter loss: percentage | “16.9%” | “4.5%” | “6.5%” |
| ≥20-letter loss: nominal p-value vs sham | “---” | “0.008” | “0.030” |
Additional analyses of BCVA loss presented in 2023
BCVA ≥15-letter loss after treatment ended: off-treatment period
Mean change in BCVA from baseline to month 12
| Measure | ANX007 EM | ANX007 EOM | Sham |
|---|---|---|---|
| Participants analyzed | “89” | “92” | “89” |
| Mean (SE) change, letters | “-1.7(1.33)” | “-2.6(1.29)” | “-4.1(1.31)” |
Low-luminance visual acuity: registry results
| Measure | ANX007 EM | ANX007 EOM | Sham |
|---|---|---|---|
| Change from baseline to month 12, least squares mean (SE), letters | “-1.4(1.29)” | “-2.8(1.25)” | “-4.8(1.31)” |
| Participants analyzed for ≥15-letter loss | “79” | “85” | “79” |
| Number of events with ≥15-letter LLVA loss | “6” | “8” | “16” |
Low-luminance visual acuity ≥15-letter loss: topline company counts
| Measure | Sham (n=79) | EM (n=79) | EOM (n=85) | ANX007 pooled (n=164) |
|---|---|---|---|---|
| Participants with ≥15-letter LLVA loss through month 12 | “20.3% (16/79)” | “10.1% (8/79)” | “11.8% (10/85)” | “11.0% (18/164)” |
| p-value vs sham | “--” | “0.076” | “0.14” | “0.051” |
Low-luminance visual acuity and deficit: final data
| Measure | Sham | EM | EOM |
|---|---|---|---|
| LLVA ≥15-letter loss: participants with loss | “16/79” | “6/79” | “8/85” |
| LLVA ≥15-letter loss: percentage | “20.3%” | “7.6%” | “9.4%” |
| LLVA ≥15-letter loss: nominal p-value vs sham | “--” | “0.0216” | “0.0497” |
| LLVD ≥15-letter worsening: participants with worsening | “13/79” | “4/79” | “8/85” |
| LLVD ≥15-letter worsening: percentage | “16.5%” | “5.1%” | “9.4%” |
| LLVD ≥15-letter worsening: nominal p-value vs sham | “--” | “0.0209” | “0.1774” |
| Mean change in LLVA at month 12 | “-4.8” | “-1.4” | “-2.8” |
| Mean change in LLVA at month 12: nominal p-value vs sham | “---” | “0.0592” | “0.2664” |
Low-luminance visual acuity ≥15-letter loss: event definition as presented in 2024
Low-luminance visual deficit: registry results
| Measure | ANX007 EM | ANX007 EOM | Sham |
|---|---|---|---|
| Change from baseline to month 12, least squares mean (SE), letters | “-0.4(1.55)” | “1.3(1.50)” | “0.6(1.57)” |
| Participants analyzed for ≥15-letter worsening | “79” | “85” | “79” |
| Number of events with ≥15-letter LLVD worsening | “4” | “8” | “13” |
Ellipsoid zone loss: photoreceptor preservation across the macula and in central subdomains
| Region | Sham participants | Vonaprument pooled participants | Reduction vs sham | Nominal p-value |
|---|---|---|---|---|
| Pan-macula, total EZ loss | “Sham (n = 67)” | “Vonaprument pooled (n = 107)” | “27% decrease” | “0.0457” |
| Central 2.0 mm, total EZ loss | “Sham (n = 25)” | “Vonaprument pooled (n = 36)” | “48% decrease” | “0.0218” |
| Central 1.5 mm, total EZ loss | “Sham (n = 22)” | “Vonaprument pooled (n = 24)” | “59% decrease” | “0.0319” |
Ellipsoid zone and central retinal pigment epithelium loss: results as reported in 2024
Subgroup analysis: BCVA ≥15-letter loss by lesion location
| Lesion location | Sham | EM | EOM | ANX007 pooled |
|---|---|---|---|---|
| Foveal | “25.0% (11/44)” | “5.9% (3/51)” | “18.4% (9/49)” | “12.0% (12/100)” |
| Non-foveal | “17.8% (8/45)” | “5.3% (2/38)” | “2.3% (1/43)” | “3.7% (3/81)” |
| p-value vs sham | “--” | “0.0019” | “0.0439” | “0.0015” |
Subgroup analysis: BCVA ≥15-letter loss by baseline low-luminance visual deficit
| Baseline LLVD | Sham | EM | EOM | ANX007 pooled |
|---|---|---|---|---|
| LLVD <30 (healthier) | “16.9% (10/59)” | “0.0% (0/56)” | “6.3% (3/48)” | “2.9% (3/104)” |
| LLVD ≥30 (less healthy) | “30.8% (8/26)” | “16.1% (5/31)” | “16.3% (7/43)” | “16.2% (12/74)” |
| p-value vs sham | “--” | “0.0016” | “0.029” | “0.0009” |
Subgroup analysis: low-luminance visual deficit worsening by baseline BCVA
| Baseline BCVA score | Sham | EM | EOM | ANX007 pooled |
|---|---|---|---|---|
| ≥55 (better vision) | “25.5% (13/51)” | “9.4% (5/53)” | “16.4% (9/55)” | “13.0% (14/108)” |
| <55 (impaired vision) | “17.9% (5/28)” | “7.7% (2/26)” | “3.3% (1/30)” | “5.4% (3/56)” |
| p-value vs sham | “--” | “0.0161” | “0.0597” | “0.0091” |
Post hoc analysis: participants with subfoveal lesions at baseline
| Measure, subfoveal population | Sham | Vonaprument EM | Vonaprument EOM |
|---|---|---|---|
| Confirmed BCVA ≥15-letter loss: participants with loss | “10/44” | “3/51” | “7/49” |
| Confirmed BCVA ≥15-letter loss: percentage | “22.7%” | “5.9%” | “14.3%” |
| Confirmed BCVA ≥15-letter loss: nominal p-value vs sham | “---” | “.0172” | “.2930” |
| LLVA ≥15-letter loss: participants with loss | “7/41” | “2/50” | “1/48” |
| LLVA ≥15-letter loss: percentage | “17.1%” | “4.0%” | “2.1%” |
| LLVA ≥15-letter loss: nominal p-value vs sham | “---” | “.0137” | “.0377” |
“76% Risk Reduction Vonaprument EM” (opens the source at this quote in a new tab)
“HR (CI) = 0.242 (0.067 to 0.881); Nominal p = .0204” (opens the source at this quote in a new tab)
“41% Risk Reduction Vonaprument EOM” (opens the source at this quote in a new tab)
“HR (CI) = 0.504 (0.225 to 1.555); Nominal p = .2784” (opens the source at this quote in a new tab)
Baseline characteristics associated with BCVA ≥15-letter loss
Number needed to treat
“Number Needed to Treat = 1 / (21.3 – 5.6) * 100= 6.4” (opens the source at this quote in a new tab)
“Number Needed to Treat EM To Avoid ≥10 LL = 10” (opens the source at this quote in a new tab)
“Number Needed to Treat EM To Avoid ≥15 LL = 7” (opens the source at this quote in a new tab)
“Number Needed to Treat EM To Avoid ≥20 LL = 8” (opens the source at this quote in a new tab)
Health-related quality of life and patient-reported outcomes
No evidence found.
Safety results
Treatment-emergent adverse events through month 12, registry results
Deaths, serious adverse events, and other adverse events, registry results
| Measure | ANX007 EM | ANX007 EOM | Sham |
|---|---|---|---|
| All-cause mortality | “2/89 (2.25%)” | “3/92 (3.26%)” | “2/89 (2.25%)” |
| Participants with serious adverse events | “21/89 (23.60%)” | “16/92 (17.39%)” | “16/89 (17.98%)” |
| Participants with other (non-serious) adverse events | “21/89 (23.60%)” | “20/92 (21.74%)” | “23/89 (25.84%)” |
Ocular serious adverse events, registry results
| Serious adverse event | ANX007 EM | ANX007 EOM | Sham |
|---|---|---|---|
| Endophthalmitis | “1/89 (1.12%)” | “2/92 (2.17%)” | “0/89 (0.00%)” |
| Retinal artery occlusion | “0/89 (0.00%)” | “1/92 (1.09%)” | “0/89 (0.00%)” |
| Neovascular age-related macular degeneration | “1/89 (1.12%)” | “0/92 (0.00%)” | “0/89 (0.00%)” |
| Dry age-related macular degeneration | “1/89 (1.12%)” | “0/92 (0.00%)” | “0/89 (0.00%)” |
| Iritis | “1/89 (1.12%)” | “0/92 (0.00%)” | “0/89 (0.00%)” |
| Vitritis | “0/89 (0.00%)” | “1/92 (1.09%)” | “0/89 (0.00%)” |
| Vitreous floaters | “1/89 (1.12%)” | “0/92 (0.00%)” | “0/89 (0.00%)” |
| Visual acuity reduced | “0/89 (0.00%)” | “0/92 (0.00%)” | “1/89 (1.12%)” |
Non-ocular serious adverse events in two or more participants in any group, registry results
| Serious adverse event | ANX007 EM | ANX007 EOM | Sham |
|---|---|---|---|
| Atrial fibrillation | “2/89 (2.25%)” | “4/92 (4.35%)” | “0/89 (0.00%)” |
| Acute myocardial infarction | “2/89 (2.25%)” | “1/92 (1.09%)” | “0/89 (0.00%)” |
| Angina pectoris | “0/89 (0.00%)” | “2/92 (2.17%)” | “0/89 (0.00%)” |
| Pneumonia | “3/89 (3.37%)” | “2/92 (2.17%)” | “0/89 (0.00%)” |
| Urinary tract infection | “1/89 (1.12%)” | “1/92 (1.09%)” | “2/89 (2.25%)” |
| Cerebrovascular accident | “2/89 (2.25%)” | “0/92 (0.00%)” | “2/89 (2.25%)” |
Non-serious adverse events at a frequency of 5% or more, registry results
| Adverse event | ANX007 EM | ANX007 EOM | Sham |
|---|---|---|---|
| COVID-19 | “12/89 (13.48%)” | “10/92 (10.87%)” | “10/89 (11.24%)” |
| Urinary tract infection | “6/89 (6.74%)” | “7/92 (7.61%)” | “12/89 (13.48%)” |
| Conjunctival haemorrhage | “7/89 (7.87%)” | “6/92 (6.52%)” | “3/89 (3.37%)” |
Adverse events of special interest: choroidal neovascularization, endophthalmitis, vascular occlusion, vasculitis, intraocular inflammation, and ischemic optic neuropathy
| Adverse event, n (%) | Sham (N=89) | Vonaprument EM (N=89) | Vonaprument EOM (N=92) |
|---|---|---|---|
| Choroidal neovascularization | “3 (3.4%)” | “4 (4.5%)” | “4 (4.3%)” |
| Endophthalmitis | “0” | “1 (1.1%)” | “2 (2.2%)” |
| Retinal vascular occlusion | “0” | “0” | “1^ (1.1%)” |
| Retinal vasculitis | “0” | “0” | “0” |
| Intraocular inflammation | “0” | “2 (2.2%)” | “1 (1.1%)” |
| Ischemic optic neuropathy | “0” | “0” | “0” |
“Iritis – 1” (opens the source at this quote in a new tab)
“Resolved with topical steroids in 2 days” (opens the source at this quote in a new tab)
“Vitritis – 1” (opens the source at this quote in a new tab)
“Resolved with topical steroids in 9 days” (opens the source at this quote in a new tab)
“Vitreous Debris – 1” (opens the source at this quote in a new tab)
“Not AESI, included because of current interest” (opens the source at this quote in a new tab)
Endophthalmitis, intraocular inflammation, and retinal artery occlusion: topline description
Choroidal neovascularization and retinal vasculitis
Study limitations
Summary: missed primary endpoint, reliance on secondary and post hoc analyses, and unpublished results
- Primary endpoint: ARCHER did not meet its primary endpoint, the rate of change (slope) in geographic atrophy lesion area by fundus autofluorescence from baseline to month 12. In the registry analysis, which included non-subfoveal participants only, the slope was 2.0837 mm²/year in 81 participants receiving pooled vonaprument and 1.9019 mm²/year in 45 participants receiving sham. Annexon reported reductions in lesion growth of 6.2% with monthly dosing (p=0.526), 1.3% with every-other-month dosing (p=0.896), and 3.7% for the pooled groups (p=0.673).
- Efficacy claims rest on secondary, exploratory, and post hoc analyses: BCVA ≥15-letter loss is a secondary outcome on the registry record and is labeled “A Prespecified Secondary Analysis” in a 2025 presentation. The Form 10-K describes the monthly-arm result as “nominally statistically significant”, and the company presentations of 2024 to 2026 label their p-values as nominal. The analyses of eyes with subfoveal lesions are labeled post hoc, and the company describes the analyses of less advanced disease, BCVA ≥10-letter and ≥20-letter loss, fellow eyes, and the off-treatment period as additional or sensitivity analyses. Mean change in BCVA at month 12 was -1.7 letters with monthly dosing, -2.6 with every-other-month dosing, and -4.1 with sham, with nominal p-values of 0.1904 and 0.3977.
- Discrepant event counts: the registry reports 4, 8, and 15 events of confirmed BCVA ≥15-letter loss (monthly, every other month, sham), defined as loss at 2 consecutive visits. The topline release reported 5 of 89 (5.6%), 10 of 92 (10.9%), and 19 of 89 (21.3%) participants, counting loss on two consecutive visits or a loss at the end of the 12-month treatment period. The 2026 presentation reports 5 of 89, 9 of 92, and 19 of 89 under “two consecutive visits through month 12 or at last study visit” (nominal p=0.0021 and 0.032), and 4 of 89, 8 of 92, and 15 of 89 when the month 12 event is confirmed at month 15 (nominal p=0.0076 and 0.0994). Under the definition that reproduces the registry counts, the every-other-month result is not nominally significant.
- Changing analyses between presentations: the topline release reported LLVA ≥15-letter loss in 8 of 79 participants (10.1%) with monthly dosing and 16 of 79 (20.3%) with sham (p=0.076), described as a “non-significant trend”. Later presentations report 6 of 79 (7.6%) with p=0.022 or 0.0216; the 2024 presentation attributes these counts to a “single LLVA ≥15-letter loss event”, and the 2026 presentation attributes the same counts to “two consecutive or last visit 15-letter loss events”. The nominal p-value for the monthly hazard ratio of 0.272 is 0.0098 in the 2024 presentation and 0.0119 in the 2026 presentation, and for the every-other-month hazard ratio of 0.504 it is 0.0788 and 0.1098. The ellipsoid zone result across the full retinal field was 29% (p=0.017) in the 2024 release and a 27% decrease (p=0.0457) in 107 vonaprument and 67 sham participants in the 2026 presentation; the central 1.5 mm and 2.0 mm subdomain analyses include 46 and 61 participants.
- No peer-reviewed publication: no journal article reporting ARCHER results was identified. The registry record states a restrictive agreement under which investigator-initiated publications wait until all protocol-defined results are published in a manuscript. The available results come from the registry, press releases, the Form 10-K, investor presentations, and congress presentations that state Annexon sponsorship, with authors who are employees and equity owners of Annexon Biosciences.
- Applicability: the treatment period was 12 months, followed by 6 months off treatment, during which the rate of BCVA ≥15-letter loss in the treated groups increased to parallel sham. Ninety-six percent of participants were enrolled in the United States. ARCHER II did not enroll individuals with baseline BCVA <45 letters, because ARCHER showed a very low incidence of BCVA 15-letter loss in that group, so the phase 3 population differs from the phase 2 population. The phase 3 trial tests monthly dosing only.
Primary endpoint not met
Restrictive publication agreement on the registry record
Post hoc analyses with nominal p-values
Sponsor employment and sponsorship of congress presentations
Phase 3 population restricted after the phase 2 results
Enrollment concentrated in the United States
AiiM OLE
Objective
Registered purpose of the extension study
Company statement of the extension study objective
Extension data intended for the label
Location and study date
Registry dates for the extension study
| Milestone | Registry record |
|---|---|
| First posted | “2026-09-08” |
| Study start (estimated) | “2026-09-30” |
| Primary completion (estimated) | “2029-07-31” |
| Study completion (estimated) | “2029-07-31” |
Registered extension study sites
“Retina Group of Florida” (opens the source at this quote in a new tab)
“Retina Vitreous Associates of Florida” (opens the source at this quote in a new tab)
“Cumberland Valley Retina Consultants” (opens the source at this quote in a new tab)
“Mid Atlantic Retina Specialists” (opens the source at this quote in a new tab)
“Asheville Eye Associates - Retina Division” (opens the source at this quote in a new tab)
“Verum Research, LLC” (opens the source at this quote in a new tab)
Extension study identifiers
| Item | Registry record |
|---|---|
| Sponsor protocol number | “ANX007-GA-03” |
| EU CT number | “2026-527023-96-00” |
| Acronym | “AiiM OLE” |
Study design
Entry into the extension after the ARCHER II Month 24 visit
Regulatory acceptance of the extension study data
Eligibility criteria
Registered inclusion and exclusion criteria for the extension study
Treatment
Registered extension study arm and intervention
Study outcomes
Rationale for using treatment-emergent adverse events as the primary endpoint
Registered primary outcome of the extension study
Statistical analysis description
Number of participants (Planned and analyzed)
Estimated enrollment in the extension study
| Item | Registry record |
|---|---|
| Estimated enrollment | “605” |
Description of analysis sets
No evidence found.
Results
Participant disposition
No evidence found.
Baseline characteristics
No evidence found.
Efficacy results
No evidence found.
Health-related quality of life and patient-reported outcomes
No evidence found.
Safety results
No evidence found.
Study limitations
Summary: extension study not yet started
The AiiM OLE study (NCT07807969) was registered as not yet recruiting, with an estimated start date of September 30, 2026 and an estimated primary completion date of July 31, 2029, so no participant data exist. It is a single-group, open-label design with no masking and no comparator arm, and its registered primary outcome is the number of participants with treatment-emergent adverse events through Month 24; any efficacy observations it yields will lack a concurrent control. Enrollment is limited to participants who completed ARCHER II and had not permanently ceased their assigned masked treatment at or before the Month 24 visit, so the extension population is a selected subset of the ARCHER II population. The company states that the extension is designed to evaluate the “longer-term profile of vonaprument for inclusion in the label”, and its 10-Q states that there is no assurance that regulators will accept data from the OLE study.
ANX007-GLA-02
Objective
Registered primary, secondary, and exploratory objectives of the phase 1b study
Published objective of the repeat-dose study
“The phase Ib study was a double-masked, randomized, sham-controlled trial evaluating 2 dose levels of ANX007 (2.5 mg and 5 mg) to determine the safety and tolerability (primary objectives) of 2 repeat monthly IVT injections (NCT04188015).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Location and study date
Registry dates for the phase 1b study
| Milestone | Registry record |
|---|---|
| Study start (actual) | “2018-07-25” |
| Primary completion (actual) | “2019-06-03” |
| Study completion (actual) | “2019-06-03” |
Study design
Registered design of the phase 1b study
Eligibility criteria
Published inclusion criteria for the phase 1b study
“In the phase Ib study, eligible patients were aged ≥ 18 years, of either sex, with primary open-angle glaucoma with a mean deviation of −3 to −24 decibels (dB) on a reliable visual field test using the Humphrey field analyzer in the study eye as determined at screening, and an IOP < 21 mm Hg at screening and day 1, with no change to the IOP treatment regimen anticipated throughout study participation.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Registered exclusion criteria for the phase 1b study
Treatment
Repeat-dose randomization and injection volumes
“In the repeat-dose phase Ib study, patients were randomized to receive 2 injections 4 weeks apart (day 1 and day 29) of sham (no ocular penetration) or 2.5 mg ANX007 or 5.0 mg ANX007. Doses were administered at volumes of 20 μL (1 mg dose), 50 μL (2.5 mg dose), and 100 μL (5 mg dose), respectively.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Sham procedure
“For the sham injection, the preparation was identical to injection with ANX007. The sham injection was performed by applying pressure to the eye at the location of a typical IVT injection using the blunt end of an empty syringe without a needle.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Registered phase 1b arms
Study outcomes
Rationale for using treatment-emergent adverse events as the primary endpoint
Registered primary and secondary outcomes of the phase 1b study
Safety assessments and follow-up in the phase 1b study
“In the repeat-dose phase Ib study, patients were followed for a total of 12 weeks for safety, tolerability, PK (unbound ANX007 concentration in serum and aqueous humor)” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The safety assessments included AEs, vital signs, physical examination, urinalysis, complete blood count, serum chemistries, best corrected visual acuity assessment, slit-lamp examination, IOP measurement, and dilated fundoscopy.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Aqueous humor C1q as a measure of retinal target engagement
“Inhibition of C1q in the aqueous humor is anticipated to represent inhibition of C1q in relevant sites of neurodegenerative ophthalmic disease within the retina.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In these animal studies, complete C1q target engagement in the aqueous humor reflected complete target engagement in the vitreous and retinal tissue, with measurable unbound drug at these sites in the back of the eye (Annexon, data on file).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Aqueous humor sampling and assays
“Aqueous humor was collected only in the phase Ib study per investigator standard of care into a tube provided for the study.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Plate-captured C1q was detected using a monoclonal mouse anti-C1q antibody-alkaline phosphatase conjugate that binds to the same site as ANX007, thus enabling measurement of free C1q levels.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Statistical analysis description
Number of participants (Planned and analyzed)
Planned and enrolled participants in the phase 1b study
“Seventeen patients (mean Humphrey visual field deviation between −3 and −24 dB) were enrolled in phase Ib and randomized to 2 monthly doses of ANX007 (sham, n = 6; 2.5 mg ANX007, n = 6; or 5 mg ANX007, n = 5).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Description of analysis sets
Descriptive analysis without hypothesis testing
“No formal comparisons or hypothesis testing were planned for comparisons between dosing levels evaluated in either study, and data are presented descriptively throughout. Descriptive statistics for categorical variables included counts and percentages. Descriptive statistics for continuous variables included means, medians, standard deviation (SD), and minimum and maximum values.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Results
Participant disposition
Treated participants and early terminations in the phase 1b study
“In the phase Ib study, 18 patients were included in the study and 17 received study treatment. One patient was randomized to receive ANX007 2.5 mg but terminated participation in the study and did not receive any study treatment due to elevated IOP on day 1.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“One patient with pseudo-exfoliative glaucoma in the sham group terminated the study early after receiving the day 1 injection due to protocol violation (pseudo-exfoliation glaucoma was not recognized as included in primary open angle glaucoma inclusion criteria).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Baseline characteristics
Demographics of the phase 1b study by arm
Efficacy results
Aqueous humor C1q target engagement at day 29
“Correspondingly, mean (SD) and median (min, max) unbound C1q at day 1 (preinjection) was 100.1 (99.9) and 51.6 (16, 254) ng/ml in sham, 110.0 (109.5) and 65.7 (23, 293) in the ANX007 2.5 mg dose group, and 110.0 (83.1) and 86.8 (14, 222) in the ANX007 5.0 mg dose groups. Unbound C1q was reduced to undetectable levels at day 29 (< 0.6 ng/ml) in aqueous humor at both dose levels in all subjects (Fig 4).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Full engagement of C1q in the aqueous humor at day 29 in all treated subjects supports monthly or less-frequent dosing of ANX007 in future clinical studies.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Aqueous humor drug concentrations at day 29
“Mean (SD) and median (min, max) ANX007 levels in aqueous humor on day 29 were 911 ng/ml (846) and 631 (225, 2539) ng/ml in the ANX007 2.5 mg dose group and 5345 ng/ml (6351) and 3111 (413, 12 512) ng/ml in the ANX007 5.0 mg dose group (Fig 3).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Systemic pharmacokinetics and pharmacodynamics after repeat dosing
“The PK and PD analyses conducted in the phase 1b study demonstrated detectable levels of ANX007 and corresponding complete reduction of free C1q in the aqueous humor following IVT injection with ANX007 at both the 2.5 and 5.0 mg dose levels through 29 days after the first injection. Importantly, no PK or PD changes were observed in the systemic circulation.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Health-related quality of life and patient-reported outcomes
No evidence found.
Safety results
Adverse events in the phase 1b study by arm
Serious, severe, and treatment-emergent adverse events after repeat dosing
“No serious AEs, severe TEAEs, or fatal AEs were reported in any group at any time during the study. A total of 6 TEAEs were reported, 2 events in each dose level. Treatment-emergent AEs included conjunctival hemorrhage, conjunctival hyperemia, eye irritation/pain, foreign body sensation in the eyes, ocular hyperemia, blurry vision, and 1 systemic TEAE of bronchitis, which was not assessed to be related to ANX007 (Table 2). All TEAEs were mild in severity and none resulted in study discontinuation. All resolved by study closure. No drug-specific safety signals were observed, and there were no clinically significant laboratory results during study.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Intraocular pressure after repeat dosing
“Intraocular pressure returned to normal levels (≤ 21 mm Hg) within 45 minutes for all patients and within 30 minutes for 16/17 (94.1%) patients. Mean IOP measurements were within normal limits (≤ 21 mm Hg) at all time points.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Best corrected visual acuity through day 84
“Between baseline and day 84, the mean (SD) logarithm of the minimum angle of resolution results for the study eye decreased (representing improved visual acuity) in the Sham (−0.073 ± 0.0485) and ANX007 2.5 mg (−0.032 ± 0.1001) groups but increased (representing worsened visual acuity) in the ANX007 5.0 mg group (0.024 ± 0.0485) (Fig 2).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Anti-drug antibodies after repeat dosing
“Low levels of ADA positivity were detected in 7 patients (1 patient in the sham group, 3 patients in the ANX007 2.5 mg group, and 3 patients in the ANX007 5 mg group). The signal in the ADA assay was marginally above the cut points. Of these, 5 patients (1 patient in the sham group, 1 patient in the ANX007 2.5 mg group, and 3 patients in the ANX007 5 mg group) were ADA-positive at all time points, including the predosing period, without any dose-related changes.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Study limitations
Summary: glaucoma population, small sample, and short follow-up
ANX007-GLA-02 enrolled participants with primary open-angle glaucoma, a population that differs from the geographic atrophy population of the phase 2 and phase 3 trials. Seventeen participants received study treatment (sham, 6; 2.5 mg, 6; 5 mg, 5), follow-up lasted 12 weeks with 2 injections given 4 weeks apart, and no formal comparisons or hypothesis testing were planned, so the results are descriptive. The safety table lists 7 participants in the 2.5-mg column and 18 overall, while the text reports 6 participants treated with 2.5 mg and 17 treated overall. Target engagement was measured in aqueous humor, which the authors state is “anticipated to represent” inhibition of C1q in the retina, supported by nonhuman primate data on file. The 5-mg dose was given in 100 μL in this study, while the ongoing phase 3 ARCHER II trial administers 5 mg in a 25-microliter dose. Low-level anti-drug antibody positivity was detected in 7 participants, including 1 in the sham group, which the authors attribute to likely false positives in the assay.
Author-stated limitations of the phase 1b study
“When considering the results of these data in a broader context, it should be noted that the relatively small sample size and descriptive nature of the analyses preclude formal clinical endpoint comparisons between the sham and treatment groups in the phase Ib study and also between the dose levels evaluated. Additional data from larger cohorts will add to our understanding of safety and efficacy at different dosing levels.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
ANX007-GLA-01
Objective
Registered primary, secondary, and exploratory objectives of the phase 1a study
Published objective of the first-in-human study
Company statement of the objectives of the glaucoma studies
Location and study date
Registry dates for the phase 1a study
| Milestone | Registry record |
|---|---|
| Study start (actual) | “2018-03-23” |
| Primary completion (actual) | “2018-08-03” |
| Study completion (actual) | “2018-08-03” |
Study design
Registered design of the phase 1a study
Dose escalation and dose-limiting toxicity criteria
“In the dose-escalation phase Ia study, patients were enrolled into the lowest open cohort in an open-label manner and received a single dose of ANX007 at 1 of 3 dose levels (1 mg, 2.5 mg, or 5.0 mg), with cohort dose escalation in the absence of any dose-limiting toxicity. Dose-limiting toxicity criteria were defined as any of the following adverse events (AEs) occurring within 2 weeks after an IVT injection and considered to be related to ANX007: intraocular inflammation of at least grade 2, using the Standardization of Uveitis Nomenclature criteria, that was unresponsive to topical corticosteroid therapy; increase in IOP > 30 mm Hg that was unresponsive to topical or oral IOP-lowering medications; or loss of best corrected visual acuity of > 3 Snellen lines from baseline, excluding a transient loss immediately after IVT injection.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Eligibility criteria
Published inclusion criteria for the phase 1a study
“In the phase Ia study, eligible patients were aged ≥ 18 years, of either sex, with primary open-angle glaucoma on stable IOP-lowering medications, with a mean deviation of −3 to −18 dB on a reliable visual field test using the Humphrey field analyzer in the study eye, and an IOP < 21 mm Hg for ≥ 4 weeks before dosing, with no change to the IOP treatment regimen anticipated throughout study participation.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Key exclusion criteria for both glaucoma studies
“For both studies, key exclusion criteria included intraocular inflammatory or infectious eye disease; uncomplicated cataract surgery < 3 months before injection; trabeculectomy, iridotomy, vitrectomy, or other incisional ocular procedures in the study eye that could affect drug distribution and excretion; and history of autoimmune or neurologic disease.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Registered exclusion criteria for the phase 1a study
Treatment
Single-dose cohorts
“Nine patients with primary open-angle glaucoma (mean Humphrey visual field deviation between −3 and −18 decibels [dB]) were enrolled in phase Ia and received single doses of ANX007 (1.0 mg, n = 3; 2.5 mg, n = 3; or 5.0 mg, n = 3).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Intravitreal injection procedure
“Intravitreal injection was performed under sterile conditions. Topical proparacaine was used for anesthesia. Lid margins were cleaned with Povidone-iodine 10% and povidone-iodine 5% was applied to the conjunctival surface, including the injection site. For ANX007 injection, the needle was inserted perpendicular to the sclera, 3.5 to 4 mm posterior to the limbus, between the vertical and horizontal rectus muscles.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Intraocular pressure was checked postinjection. Topical antibiotics were not used postinjection.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Study outcomes
Rationale for using adverse events as the primary endpoint
Registered outcomes of the phase 1a study
Follow-up and sampling in the phase 1a study
“In the dose-escalation phase Ia study, patients were followed for a total of 8 weeks for safety, tolerability, PK (unbound ANX007 serum concentration)” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In the single-dose study, samples for PK and PD analyses were obtained preinjection and 3 hours postinjection on day 1, and on days 2, 4, 8, and 15. Samples for the evaluation of serum ADAs were obtained preinjection, on study day 29, and at the follow-up visit on day 56.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Statistical analysis description
Number of participants (Planned and analyzed)
Planned and enrolled participants in the phase 1a study
Description of analysis sets
Safety and immunogenicity analysis population
“Pooled data are reported by dose level of ANX007 by study and non-study eye, where applicable. Patients who received ≥ 1 injection of ANX007 were assessed for safety and immunogenicity endpoints. The incidences of treatment-emergent AEs were tabulated by system organ class and preferred term, as well as by ocular or systemic intensity, or Common Terminology Criteria for Adverse Events grade, and by relationship to ANX007.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Results
Participant disposition
Baseline characteristics
Demographics of the phase 1a study by dose cohort
Efficacy results
Health-related quality of life and patient-reported outcomes
No evidence found.
Safety results
Adverse events in the phase 1a study by dose cohort
Ocular and systemic adverse events after a single dose
“Eight ocular TEAEs were reported in the study eye, including ocular irritation, conjunctival hemorrhage, and conjunctival hyperemia, and 1 systemic TEAE was reported (sinusitis) which was not assessed to be related to ANX007 (Table 2). No ocular TEAEs were reported in the non-study eye for any patient. All AEs were mild in severity and resolved by the end of the study and there were no clinically significant laboratory results at any time during the on-therapy period.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“No dose-limiting toxicities were observed.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Safety across both glaucoma studies
Intraocular pressure after a single dose
“Intraocular pressure returned to normal levels (defined as within 5 mm Hg of baseline or ≤ 21 mm Hg) at 30 minutes for all patients. Mean IOP measurements were within normal limits (≤ 21 mm Hg) at all time points (Table 3).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Study limitations
Summary: glaucoma population, small open-label cohorts, and serum-only pharmacodynamics
ANX007-GLA-01 was a first-in-human, open-label, single-dose escalation study in 9 participants with primary open-angle glaucoma (3 per dose cohort of 1.0, 2.5, and 5.0 mg), a population that differs from the geographic atrophy population of the phase 2 and phase 3 trials. The study had no masking and no control arm, follow-up lasted 8 weeks, and sample sizes were “determined by clinical and practical, rather than statistical, considerations”, with data presented descriptively. Aqueous humor was not sampled in this study, so pharmacokinetics and target engagement were assessed in serum only, where unbound ANX007 was not detected. The article states that there were no treatment-emergent adverse events after single injections, and in the same paragraph reports 8 ocular treatment-emergent adverse events and 1 systemic event, with all 9 participants (100.0%) having any treatment-emergent adverse event in its Table 2. The 5-mg dose was given in 100 μL, while the ongoing phase 3 ARCHER II trial administers 5 mg in a 25-microliter dose.